Peripheral blood lymphocytes influence human papillomavirus infection and clearance: a retrospective cohort study

[1]  S. Grénman,et al.  Peripheral Blood T-lymphocyte Phenotypes in Mother-Child Pairs Stratified by the Maternal HPV Status: Persistent HPV16 vs. HPV-Negative: A Case-Control Study , 2022, Viruses.

[2]  L. Sollid.  Epstein-Barr virus as a driver of multiple sclerosis , 2022, Science Immunology.

[3]  A. C. de Freitas,et al.  Detection of Human Papillomavirus DNA in Paired Peripheral Blood and Cervix Samples in Patients with Cervical Lesions and Healthy Individuals , 2021, Journal of clinical medicine.

[4]  Adriana Gutiérrez-Hoya,et al.  NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy , 2021, Cells.

[5]  H. Cui,et al.  Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers , 2021, Frontiers in Immunology.

[6]  Risnawati,et al.  HPV 52 most dominant Human Papillomavirus (HPV) genotype in women infected by Human Immunodeficiency Virus (HIV) that get antiretroviral treatment (ART) , 2020 .

[7]  C. Flowers,et al.  Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society , 2020, CA: a cancer journal for clinicians.

[8]  E. Ramírez,et al.  Detection and quantitation of human papillomavirus DNA in peripheral blood mononuclear cells from blood donors , 2019, Journal of medical virology.

[9]  E. King,et al.  HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC , 2019, Cancer Immunology Research.

[10]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[11]  A. Benzaken,et al.  High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas , 2018, Virology Journal.

[12]  N. Christensen,et al.  The Mouse Papillomavirus Infection Model , 2017, Viruses.

[13]  L. Laimins,et al.  Manipulation of the innate immune response by human papillomaviruses. , 2017, Virus research.

[14]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[15]  S. Morré,et al.  Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A Review , 2017, Journal of immunology research.

[16]  I. Frazer,et al.  Role of Ultraviolet Radiation in Papillomavirus-Induced Disease , 2016, PLoS pathogens.

[17]  R. Roden,et al.  Immunologic Control of Mus musculus Papillomavirus Type 1 , 2015, PLoS pathogens.

[18]  Marc D. Ryser,et al.  HPV Clearance and the Neglected Role of Stochasticity , 2015, PLoS Comput. Biol..

[19]  Xiaofei Yan,et al.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model , 2014, Human vaccines & immunotherapeutics.

[20]  Ingrid B Borecki,et al.  Polymorphisms in immune mediators associate with risk of cervical cancer. , 2014, Gynecologic oncology.

[21]  M. Pawlita,et al.  A case of recurrent respiratory papillomatosis with malignant transformation, HPV11 DNAemia, high L1 antibody titre and a fatal papillary endocardial lesion , 2014, Virology Journal.

[22]  B. Říhová,et al.  High Level of Tregs Is a Positive Prognostic Marker in Patients with HPV-Positive Oral and Oropharyngeal Squamous Cell Carcinomas , 2014, BioMed research international.

[23]  Q. Wei,et al.  Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma , 2013, Molecular Cancer.

[24]  A. Aguilar-Lemarroy,et al.  Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications , 2012, BMC Immunology.

[25]  R. Longhi,et al.  CD4+ T cells against human papillomavirus‐18 E7 in patients with high‐grade cervical lesions associate with the absence of the virus in the cervix , 2010, Immunology.

[26]  M. Stanley,et al.  Characterising the local immune responses in cervical intraepithelial neoplasia: a cross‐sectional and longitudinal analysis , 2008, BJOG : an international journal of obstetrics and gynaecology.

[27]  R. Longhi,et al.  IFN-γ Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions1 , 2007, The Journal of Immunology.

[28]  S. H. van der Burg,et al.  Detection of human papillomavirus type 18 E6 and E7‐specific CD4+ T‐helper 1 immunity in relation to health versus disease , 2006, International journal of cancer.

[29]  W. Quint,et al.  High Prevalence of Human Papillomavirus (HPV) Infections and High Frequency of Multiple HPV Genotypes in Human Immunodeficiency Virus-Infected Women in Brazil , 2002 .

[30]  Y. Soong,et al.  Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Soulillou,et al.  Lymphocyte subsets, phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in sarcoidosis. , 1985, Thorax.

[32]  L. Lazarenko,et al.  Production of interferons and change of the lymphocyte subpopulation phenotype in peripheral blood at cervical papillomavirus infection , 2008, Folia Microbiologica.

[33]  L. Lazarenko,et al.  Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection , 2008, Folia Microbiologica.

[34]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..